To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.6729146.
Tedizolid phosphate 200 mg, once daily for 6 days, has recently been approved for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSIs) in several countries; however, clinical experience in real-life settings is currently limited. Here, we report on the use of tedizolid with an extended treatment duration for complex and severe ABSSSIs in real-world clinical settings.
Two patients with cellulitis and two patients with surgical site infection (SSI), aged 26–60 years, were treated with tedizolid phosphate 200 mg, intravenous/oral (IV/PO) or IV only, once daily at four different institutions.
Two morbidly obese patients had non-necrotizing, non-purulent severe cellulitis, which were complicated by sepsis or systemic inflammatory response syndrome plus myositis. One female patient failed on first-line empiric therapy with IV cefalotin, clindamycin and imipenem (3–4 days), and was switched to IV/PO tedizolid (7 + 5 days). One male patient received IV clindamycin plus IV/PO tedizolid (5 + 5 days), but clindamycin was discontinued on Day 3 due to an adverse event. For both patients, clinical signs and symptoms improved within 72 h, and laboratory results were normalized by Days 7 and 8, respectively. Two other patients (one obese, diabetic female with chronic hepatitis and chronic obstructive pulmonary disease) had complicated SSIs occurring 10 days after hernia repair with mesh or 3 months after spinal fusion surgery with metal implant. First patient with previous methicillin-resistant Staphylococcus aureus (MRSA) bacteremia received a 7-day tedizolid IV course empirically. The second patient with culture-confirmed MRSA infection received a 14-day IV course. Both patients responded within 72 h, and local and systemic signs normalized by end of treatment. There were no reports of thrombocytopenia.
Tedizolid phosphate 200 mg for 7–14 days was a favored treatment option for patients with severe/complex ABSSSIs, and was effective following previous treatment failure or in late-onset infections.
Editorial assistance and the article processing charges were funded by Bayer AG, Berlin, Germany.
Sutherland M, Parent A. Diagnosis and management of cellulitis: a dermatology perspective. Br J Comm Nurs. 2017;22(6):272–5. CrossRef
Pfaller MA, Flamm RK, Jones RN, Farrell DJ, Mendes RE. Activities of tedizolid and linezolid determined by the reference broth microdilution method against 3032 Gram-positive bacterial isolates collected in Asia-Pacific, Eastern Europe, and Latin American countries in 2014. Antimicrob Agents Chemother. 2016;60(9):5393–9. CrossRefPubMedPubMedCentral
Sivextro® (tedizolid phosphate). Prescribing information. Whitehouse Station, NJ, USA: Merck & Co; 2017.
Sivextro® (tedizolid phosphate). Prescribing information. Mexico: Bayer; 2016.
Sivextro® (tedizolid phosphate). Prescribing information. Singapore: Bayer; 2016.
Sivextro® (tedizolid phosphate). Summary of product characteristics. Russia: Bayer; 2016.
Wijaya L, Hsu LY. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Proc Singapore Healthc. 2010;19:212–9. CrossRef
ECDC. Antimicrobial resistance surveillance in Europe 2015. https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2015. Accessed July 14 2017.
Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66:82–98. CrossRefPubMed
Zyvox® (linezolid). Prescribing information. New York, NY, USA: Pfizer; 2015.
Biedenbach DJ, Bouchillon SK, Johnson B, Alder J, Sahm DF. In vitro activity of tedizolid against Staphylococcus aureus and Streptococcus pneumoniae collected in 2013 and 2014 from sites in Latin American countries, Australia, New Zealand, and China. Eur J Clin Microbiol Infect Dis. 2016;35(12):1933–9. CrossRefPubMed
Sandison T, De Anda C, Fang E, Das AF, Prokocimer P. Clinical response of tedizolid versus linezolid in acute bacterial skin and skin structure infections by severity measure using a pooled analysis from two phase 3 double-blind trials. Antimicrob Agents Chemother. 2017;61(5):e02687–16. CrossRefPubMedPubMedCentral
Patel H, Khoury H, Girgenti D, Welner S, Yu H. Burden of surgical site infections associated with select spine operations and involvement of Staphylococcus aureus. Surg Infect. 2017;18(4):461–73. CrossRef
Rondina MT, Walker A, Pendleton RC. Drug-induced thrombocytopenia for the hospitalist physician with a focus on heparin-induced thrombocytopenia. Hosp Pract (1995). 2010;38(2):19–28.
Friedman DN, Pollard J, Huffman S, et al. Randomized controlled trial of short course intravenous therapy for cellulitis and erysipelas of the lower limb (Switch): study protocol and pilot trial results. J Clin Trials. 2014;4:200. https://doi.org/10.4172/2167-0870.1000200.
Nathwani D, Corey R, Das AF, Sandison T, De Anda C, Prokocimer P. Early clinical response as a predictor of late treatment success in patients with acute bacterial skin and skin structure infections: retrospective analysis of 2 randomized controlled trials. Clin Infect Dis. 2017;64:214–7. CrossRefPubMed
- Real-Life Evidence for Tedizolid Phosphate in the Treatment of Cellulitis and Wound Infections: A Case Series
Nana N. Khachatryan
Javier de la Cabada-Bauche
Hoe N. Leong
Mark H. Wilcox
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
e.Med Kampagnen-Visual, Mail Icon II